Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
137
resultados
Última actualización
21/11/2024 [06:58:00]
Resumen de: EP4465304A1
Blood glucose monitoring is a difficult task that people with diabetes often have to perform on their own. Accurate and timely prediction is vital for making decisions and recommending corrective actions. Therefore, there is a need to develop effective and accurate glucose prediction methods that allow the development of safe blood glucose monitoring systems using simple and convenient devices for the patient.The present invention describes a non-invasive method and system for the prediction of glucose values, based on the estimation from variables measured with an activity wristband. The system uses variables that are not directly related to glucose to estimate and predict glucose values and generates alerts to dangerous situations of hypoglycemia and hyperglycemia.
Resumen de: EP4464246A2
In some embodiments, a sensor assembly for a continuous glucose monitoring system is provided that includes (1) a sensor carrier having a sensor unit receiving area and an electronics receiving area, the electronics receiving area including a substrate; (2) a sensor unit having a sterilized region, the sterilized region including at least a portion of a sensor and an introducer; and (3) electronics for the continuous glucose monitoring system. The sensor unit is positioned within the sensor unit receiving area of the sensor carrier and the electronics are positioned on the substrate within the electronics receiving area of the sensor carrier so as to form a sensor assembly having the sensor electrically connected to the substrate of the electronics receiving area while maintaining sterilization of the sterilized region of the sensor unit. Numerous other aspects are provided.
Resumen de: EP4465307A2
Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are provided. The data can be displayed on a hand-held display device (16) having a display (608) such as a key fob device (14) including a user interface, such as an LCD (602) and one or more buttons (604) that allows a user to view data, and a physical connector, such as USB port (606).
Resumen de: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: GB2630057A
A current measurement device for an analyte monitoring system, such as an implantable blood glucose monitor, comprises: an amperometric sensor connected to a Resettable Integrator Circuit (RIC) with a capacitor 504 charged by the current flowing from the sensor, and a voltage measurement system configured to sample a voltage at the RIC output 506. The sampled voltage is indicative of the charge in the capacitor and hence of current and analyte concentration. A controller starts a measurement cycle by charging the capacitor and ends the cycle by resetting the RIC using a switch 505a to discharge the capacitor. The voltage may be sampled at a first time close to the start of the cycle to give an indication of the rate of charging of the capacitor; this may then be used to calculate a second sampling time to measure voltage more accurately before the capacitor saturates. The device may also be used for sensing other analytes such as pollutants.
Resumen de: GB2630155A
Estimating concentration of a target substance (e.g. glucose, hormones, toxins, biomarkers etc) in a subject by receiving an electric signal corresponding to an amount of target substance extracted into a sensor reservoir 108 through a set of dermal channels 204 (e.g. hair follicles or microneedles), and determining the number of dermal channels in the set. Flux of the analyte through a selected number of dermal channels is determined based on the electric signal and number of dermal channels . A reference flux of a reference substance through the selected number of dermal channels at a reference concentration is obtained (e.g. from a look-up table or measurements), and concentration of the analyte is estimated based on the analyte flux, reference flux and reference concentration. Also disclosed is an analyte extraction and detection sensor 100 comprising a sensor pixel 110 having a substrate 102 with at least one reservoir 108 and a set of electrodes 112. The set of electrodes includes extraction electrodes for iontophoretic extraction of the analyte and the reference substance into the reservoir, target detection electrodes for detecting the amount of analyte in the reservoir, and reference detection electrodes for detecting the amount of reference substance in the reservoirs.
Resumen de: US2024381061A1
Provided relates to a communication connection method for a continuous glucose monitoring system which may comprise: a step in which, in order to connect communication between a communication terminal and a sensor transmitter attached to a human body so as to continuously monitor biometric information of the human body, the communication terminal receives information of the sensor transmitter from the sensor transmitter; a step of determining, on the basis of the received information, whether the sensor transmitter is a new sensor transmitter or an already used sensor transmitter; and a step in which, when the sensor transmitter is an already used transmitter, communication connection is controlled on the basis of use information of the already used sensor transmitter.
Resumen de: US2024377383A1
The present disclosure provides methods of processing data provided by a transcutaneous or subcutaneous glucose sensor utilizing different algorithms to strike a balance between signal responsiveness accompanied by signal noise and the introduction of error associated with that noise. The methods utilize the strengths of a lag correction algorithm and a smoothing algorithm to optimize the quality and value of the resulting data (glucose concentrations and the rates of change in glucose concentrations) to a continuous glucose monitoring system. Also provided are systems and kits.
Resumen de: US2024374823A1
Techniques for contextual adjustment of insulin adjustment curves are provided. In some embodiments, the techniques may involve identifying a reference insulin absorption parameter for a patient based on demographic information. The techniques may further involve determining an adjusted insulin absorption parameter based on the reference insulin absorption parameter and context of the patient. The techniques may further involve delivering insulin to the patient based on the adjusted insulin absorption parameter.
Resumen de: US2024374171A1
Disclosed is a system of non-invasive optical rotation angle sensing polarimeter for aqueous glucose concentration measurement. A linear polarization angle is set at 45° along propagation axis, the polarized beam transmitting aqueous humor and the polarized beam splitter whose polarization directions are orthogonal at 0° and 90° of rotation in the directions of propagation axes; difference of intensities of the orthogonal polarization components is measured in a balanced detector configuration able to obtain Stokes vector component S1 which relates to the optical rotation angle and aqueous glucose concentration under common noise rejection mode, the sum of the intensities to normalize S1 enables reduction of the optical intensity fluctuation noise too.
Resumen de: US2024374173A1
Methods, devices, and systems may use a kinetic model to determine physiological parameters related to the kinetics of red blood cell glycation, elimination, and generation. Such physiological parameters can be used, for example, to determine a more reliable calculated HbA1c. In another example, a method may comprise: receiving a plurality of glucose levels over a time period; receiving a glycated hemoglobin (HbA1c) level corresponding to an end of the time period; determining at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), a red blood cell elimination constant (kage), and an apparent glycation constant (K), based on (1) the plurality of glucose levels and (2) the HbA1c level; and adjusting a glucose level target based on the at least one physiological parameter.
Resumen de: US2024376513A1
The present invention relates to: a transition metal complex having a bidentate ligand which includes pyrazole, triazole, tetrazole, oxadiazole, thiadiazole, or the like, wherein the transition metal complex can be used as an electron transfer mediator in a continuous blood glucose monitor and the like for measuring blood glucose concentration; and an oxidation-reduction polymer comprising same. The transition metal complex and the oxidation-reduction polymer can quickly and smoothly exchange electrons between an enzyme and an electrode, and thus can be effectively used in a continuous blood glucose biosensor.
Resumen de: US2024374813A1
Exemplary embodiments calculate a user's progress towards maximum adapted system performance when utilizing a drug delivery device such as an insulin pump and display this progress to the user. Further embodiments calculate potential changes to a particular user's interaction with the system given a history of glucose and insulin deliveries and provide guidance to that user. This can be used, for example, to change how the user splits up their basal and bolus doses to improve metrics such as time-in-range, incidences of hyper- or hypo-glycemia, time in hyper- or hypo-glycemia, mean glucose, etc. It may also be used to speed the above-described adaptation process by suggesting changes that the user can make to achieve stability more quickly.
Resumen de: AU2024227563A1
Abstract A monitoring feature, such as, for example, a pen cap, for an insulin delivery device may include at least one circuit adapted to detect at least one of a capping or decapping of the pen cap from an insulin pen and a processor for using information to the at least one of a capping or decapping of the pen cap. A monitoring feature for an insulin delivery device includes at least one circuit adapted to detect use of the insulin delivery device. WO 2019/118531 PCT1US20181065067 1/3,9 4 > Mr~ zo ul uJL U 0-* C~C) --- -- ------ 4 (AU) LI IcrIT i -i .-I~~T I II r
Resumen de: US2024374814A1
An infusion system comprising: a device for delivering insulin to a user, the device configured to be mounted the user; a CGM sensor for measuring glucose level in the user and an infusion needle for delivering the insulin to the user; a needle cartridge assembly for supporting the CGM sensor and/or the infusion needle, the needle cartridge assembly configured to move from (1) a telescoping position above the device for delivering insulin, wherein the CGM sensor and/or infusion needle are/is in a retracted position within the device for delivering insulin to (2) an advanced position within the device, wherein the infusion needle and/or CGM sensor are/is in a deployed position inserted into a subcutaneous tissue of the user's skin; and a detachable activation mechanism for (a) moving the needle cartridge assembly from the telescoping position to the advanced position and for (b) releasing the device for delivering insulin upon activation of the detachable activation by the user.
Resumen de: US2024374170A1
A system for measuring one or more analytes using a real-time, non-invasive radio frequency analyte detection device. The system includes a wearable device attached to a body part, using transmit and receive antennas to send and receive RF signals. The system converts received signals into a digital processor-readable format, compares them with standard waveforms, and utilizes machine learning to identify health parameters. The device or devices measure insulin and glucose levels to determine the effect of insulin administration and predict when insulin will be needed. This data is sent to an admin network which also collects data from a patient or healthcare professional on when insulin is administered and in what dosage. This data is analyzed to recommend when insulin should be administered again and at what dosage.
Resumen de: US2024374176A1
An electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively. The electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein, with the voltage source, an electric potential different from the potential of the common potential conductor section can be provided to the first electrical connection, and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.
Resumen de: EP4461219A2
Methods, computers, and systems used to improve accuracy of analyte level measurement of an in vivo positioned analyte sensor are disclosed herein. The methods, computers, and systems disclosed herein may be used to provide a calibrated analyte level. Specific embodiments relate to methods, computers, and systems for improving accuracy of glucose measurement of an in vivo positioned glucose sensor.
Resumen de: WO2023133231A1
A system and method for personalized calibration for glucose sensing. In some embodiments, the method includes obtaining a plurality of first glucose measurements from a subject, at a plurality of first sampling times during a time interval, using a first glucose sensor; obtaining a plurality of second glucose measurements from the subject, at a plurality of second sampling times during the time interval, using a second glucose sensor; and estimating a first in-vivo calibration parameter for the first glucose sensor and the second glucose sensor, based on the first glucose measurements and the second glucose measurements, wherein a first in-vivo time-constant, relating blood glucose to an output of the first glucose sensor, is different from a second in-vivo timeconstant, relating blood glucose to an output of the second glucose sensor.
Resumen de: US2024370162A1
A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Resumen de: US2024371492A1
Techniques disclosed herein relate generally to diabetes therapy management. In some examples, the techniques involve obtaining therapy-related data (e.g., including sensor glucose data and meal data) of a user of an insulin delivery device for a time period of a plurality of time periods, determining whether the therapy-related data associated with the time period is well-fit data by determining whether a physiological model for the user can be fitted to the therapy-related data associated with the time period, determining one or more parameters of the physiological model by fitting the physiological model to well-fit data associated with the time period, and causing the insulin delivery device to deliver insulin to the user based on the one or more parameters of the physiological model.
Resumen de: US2024366122A1
Wireless, lightweight, and multifunctional chemical sensors and methods for detection of biomarkers in bodily fluids are described. Systems and methods are directed to an LC (inductor-capacitor) resonance circuit configured to detect multiple biomarkers in bodily fluids of a subject through frequency modulation. The system may be comprised within a wearable device or within a medical implant, depending on the implementation. The body fluid may comprise sweat, cerebrospinal fluid, blood, saliva, tears, mucus, gastric acid, and/or urine, for example. The biomarkers may comprise Na+, K+, Ca2+, H+, Cl—, glucose, urea, lactate, glutamate, serotonin, cortisol, dopamine, cytokines, and/or epinephrine, for example.
Resumen de: US2024366118A1
This invention provides methods and devices for the non-invasive measurement of select substances in human tissue such as, for example, blood glucose. The non-invasive methods and devices use a light source such as a laser diode for transmitting light energy pulses into human tissue. A piezoelectric component and/or ultrasonic transducer detects vibration of the tissue and generates an acoustic signal that is transmitted to a microcontroller. The concentration of the substance, for example, blood glucose is measured using at least one algorithm. Preferably, the device incorporates embedded machine learning (ML), artificial intelligence (AI), internet of things (IoT), app, and blockchain programming, wherein the programming is designed to encrypt and/or deidentify personal data and measurements.
Resumen de: US2024366874A1
A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining an insulin-on-board (IOB) value, wherein the IOB value is a quantity of insulin remaining in a patient following delivery of a bolus of insulin, scaling a total daily dose (TDD) value by a factor, to generate a result having a value that is less than the TDD value, based on determining that the IOB value is greater than the result, identifying a condition in which the patient's glucose level will continue to decrease after suspension of basal insulin dosage delivery, and responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
Nº publicación: WO2024229007A2 07/11/2024
Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Resumen de: WO2024229007A2
Embodiments relate to systems and methods for developing and implementing a model. Developing the model can involve receiving an insulin dosing rule (IDR) including plural metabolic states (Xs) and corresponding insulin dosage recommendations (Us), generating a saturated data set with the plural Xs and corresponding Us so that the saturated data set has optimal data density, generating a saturated look-up table (STL) with the saturated data set, and encoding the STL into a neural network. Implementing the model can involve receiving a measurement indicative of a metabolic state (Xm), implementing a model a SLT encoded into a neural network, the SLT including a saturated data set of optimal data density, wherein implementation of the model applies the Xm to the SLT to identify a corresponding U, and monitoring, analyzing, or influencing a concentration of glucose levels in a fluid using the identified U.
BOPI
Sede Electrónica
